Several biotech stocks have outperformed the struggling market this year. This list includes Vertex Pharmaceuticals (NASDAQ: VRTX), Exelixis (NASDAQ: EXEL), and Amgen (NASDAQ: AMGN). Of course, the market downturn isn't over, and these three drugmakers could still feel the effects of macro headwinds and geopolitical tensions in the foreseeable future.

With an uncertain near-term outlook, it would be unwise to bet on these companies to continue beating the market in the short run. However, all three have the tools to deliver solid returns in the long run. Let's consider why these three biotechs are solid buys for the next decade.

Continue reading

Source Fool.com